CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
On November16, 2017, Catalyst Biosciences, Inc., a Delaware corporation (the “Company”) entered into an office lease agreement (the “Lease Agreement”) with BXP 611 Gateway Center LP, a Delaware limited partnership (the “Landlord”) to lease approximately 8,606 rentable square feet of space located on the seventh (7th) floor of 611 Gateway Boulevard, South San Francisco, California (the “Premises”).
The term of the Lease Agreement (“the Lease Term”) is five (5)years and two (2)months. The Lease Term start date (the “Commencement Date”) shall be the earlier of (i)the date the Company commences to conduct business on the Premises, and (ii)the later of (a)March1, 2018 (as may be extended by Landlord Delay, as defined in the Lease Agreement) and (b)the completion of certain construction improvement projects on the Premises, as described in the Lease Agreement.
Base rent (the “Base Rent”) for the first year of the Lease Term is approximately $356,288, with an increase in annual base rent of approximately 3% in each subsequent year of the Lease Term. In addition to the Base Rent, the Company shall pay a share of the annual Building Direct Expenses (as defined in the Lease Agreement) and Capital Expenses (as defined in the Lease Agreement). The Lease Agreement also provides a tenant improvement allowance in the amount of $430,300 and, at the Company’s election, an additional tenant improvement allowance of up to $86,060.
The above description of the Lease Agreement is qualified in its entirety by reference to the full text of the Lease Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.
Item 1.01 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information set forth in Item 1.01 above is incorporated by reference into this Item 1.01.
| Item 1.01 | Financial Statements and Exhibits. |
(d) Exhibits.
CATALYST BIOSCIENCES, INC. ExhibitEX-10.1 2 d465134dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 OFFICE LEASE 611 GATEWAY BOULEVARD BXP 611 GATEWAY CENTER LP,…To view the full exhibit click here
About CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO)
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.